Academy

Nitin Jain, MD - CLL Highlights

Rami Komrokji, MD - MDS Highlights

Panel Discussion

Naveen Pemmaraju, MD - BPDCN Highlights

Branko Cuglievan, MD - Pediatric Leukemia Highlights

Hagop Kantarjian, MD - CML Highlights

Panel Discussion

Hagop Kantarjian, MD - Current and Future Research Directions in AML

Joseph D. Khoury, MD - The Genetic Landscape and Molecular Diagnostics in AML

Harry P. Erba, MD - Optimizing Frontline Therapy for FLT3 Mutated AML Patients Eligible for Intensive

Amir Fathi, MD - Genomic Strategies to Guide the Choice of Invasive Treatment Strategies in Non-FLT3m AML

Sanam Loghavi, MD - Diagnostic and Molecular Work-up of Newly Diagnosed AML – The Pathologist’s Perspective

Panel Discussion

Charles Mullighan, MD - Molecular Biology

Elias Jabbour, MD - Philadelphia +ve ALL

Aaron Logan, MD - Ph-ve ALL MRD

Cristina Papayannidis, MD - New Targets in ALL

Panel Discussion

Alexander Perl, MD - Updates on the Management and Mechanisms of Resistance in R/R FLT3m AML

Charlie Craddock, MD - Emerging Strategies to Improve Outcome of Allo-transplant in AML

Farhad Ravandi, MD - How do I Assess for MRD in Clinical Practice and How do I Use MRD to Guide Post-remission Therapy

Courtney DiNardo, MD - How do I use IDH Inhibitors in Frontline and R/R Setting: Single Agent Versus Combinations

Eytan Stein, MD - Current Status and Future Directions with Menin Inhibitors in AML

Panel Discussion

Elias Jabbour, MD - Integration of Immune-therapy into Frontline ALL – HCVAD Experience

Mark Litzow, MD - Integration of Immune-therapy into Frontline ALL – Regimens

Wendy Stock, MD - AYA ALL

Ibrahim Aldoss, MD - Transplant in ALL

Panel Discussion